CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 2.3%

CRISPR Therapeutics AG (NASDAQ:CRSP)’s stock price traded up 2.3% during trading on Friday . The company traded as high as $58.45 and last traded at $56.32. 579,291 shares changed hands during trading, a decline of 67% from the average session volume of 1,761,138 shares. The stock had previously closed at $55.07.

Analyst Upgrades and Downgrades

CRSP has been the subject of several recent research reports. Citigroup increased their price target on shares of CRISPR Therapeutics from $88.00 to $89.00 and gave the stock a “buy” rating in a research report on Thursday, April 18th. Wolfe Research began coverage on shares of CRISPR Therapeutics in a research report on Thursday, February 15th. They issued a “peer perform” rating for the company. Barclays lifted their target price on CRISPR Therapeutics from $61.00 to $80.00 and gave the company an “equal weight” rating in a research note on Thursday, February 22nd. Chardan Capital boosted their price objective on CRISPR Therapeutics from $110.00 to $112.00 and gave the stock a “buy” rating in a report on Thursday, February 22nd. Finally, Royal Bank of Canada lifted their price target on shares of CRISPR Therapeutics from $57.00 to $66.00 and gave the stock a “sector perform” rating in a research report on Thursday, February 22nd. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $76.29.

CRISPR Therapeutics Stock Performance

The company has a fifty day moving average price of $67.75 and a two-hundred day moving average price of $64.17. The company has a market cap of $4.74 billion, a P/E ratio of -28.52 and a beta of 1.80.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Wednesday, February 21st. The company reported $1.10 earnings per share for the quarter, beating analysts’ consensus estimates of $0.15 by $0.95. The company had revenue of $201.20 million during the quarter, compared to the consensus estimate of $148.72 million. The firm’s revenue for the quarter was up 3253.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.41) earnings per share. Research analysts anticipate that CRISPR Therapeutics AG will post -6.24 EPS for the current year.

Insider Transactions at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 19,582 shares of the company’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $59.91, for a total value of $1,173,157.62. Following the transaction, the chief executive officer now directly owns 208,122 shares in the company, valued at $12,468,589.02. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, General Counsel James R. Kasinger sold 1,913 shares of the stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $79.67, for a total transaction of $152,408.71. Following the sale, the general counsel now owns 57,371 shares of the company’s stock, valued at $4,570,747.57. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Samarth Kulkarni sold 19,582 shares of the firm’s stock in a transaction on Monday, April 15th. The stock was sold at an average price of $59.91, for a total value of $1,173,157.62. Following the completion of the transaction, the chief executive officer now owns 208,122 shares in the company, valued at approximately $12,468,589.02. The disclosure for this sale can be found here. In the last three months, insiders sold 83,992 shares of company stock worth $6,132,335. 4.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On CRISPR Therapeutics

Hedge funds have recently bought and sold shares of the company. Jump Financial LLC grew its position in CRISPR Therapeutics by 194.7% during the 3rd quarter. Jump Financial LLC now owns 33,307 shares of the company’s stock worth $1,512,000 after acquiring an additional 22,006 shares during the last quarter. Invesco Ltd. increased its position in CRISPR Therapeutics by 1.5% in the 3rd quarter. Invesco Ltd. now owns 136,123 shares of the company’s stock valued at $6,179,000 after acquiring an additional 2,061 shares during the period. ARK Investment Management LLC lifted its holdings in shares of CRISPR Therapeutics by 19.2% during the fourth quarter. ARK Investment Management LLC now owns 8,536,104 shares of the company’s stock worth $534,360,000 after purchasing an additional 1,372,986 shares during the period. Prime Capital Investment Advisors LLC bought a new stake in shares of CRISPR Therapeutics in the fourth quarter worth $206,000. Finally, Baker Chad R increased its holdings in CRISPR Therapeutics by 89.1% in the fourth quarter. Baker Chad R now owns 98,520 shares of the company’s stock valued at $6,167,000 after purchasing an additional 46,420 shares during the period. 69.20% of the stock is owned by institutional investors.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.